

	Date	Presenter	Title	Journal	Year	Vol	Page	
	4/4	坂本	Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation	Blood	2023	140(23)	2500-2513	
			Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial	JAMA	2017	318(6)	557-566	
			Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Phase 3 Trial	JAMA Oncol	2023	e227605		
		一瀬	Molecular profiling of EBV associated diffuse large B-cell lymphoma	Leukemia	2023	37(3)	670-679	
	4/11	安東	A neutrophil response linked to tumor control in immunotherapy	Cell	2023	186	1448-1468	
			T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants	Cell	2023	186	1432-1447	
			Neutrophil-activating therapy for the treatment of cancer	Cancer cell	2023	41	356-372	
		松本	Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents	Blood	2023			
	4/18	児嶋	Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase 3 Trial	Clin Oncol	2023	41(2)	327-335	
			Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma	Blood adv	2023	7(7)	1130-1136	
		クリニック学生	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial	Nat med	2022	28(2)	325-332	
	4/25	蓬萊	Diagnosis and Management of Adult Malignancy-Associated Hemophagocytic Lymphohistiocytosis	Cancers(Basel)	2023	15(6)	1839	
			Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab	Cancer	2013	60(1)	101-109	
			Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis	N Engl J med	2020	382(19)	1811-1822	
			JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation	Blood	2020	136(6)	657-668	
		加藤	Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas	J Clin Oncol	2023	41(9)	1684-1694	
	5/2	清水	Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study	J Clin Oncol	2023			
			Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy	Cancer Immuno	2017	66(7)	877-890	
			Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy	Clin Cancer Res	2012	18(6)	1611-1618	
		糸永	RUNX1 isoform disequilibrium promotes the development of trisomy 21-associated myeloid leukemia	Blood	2023	141(10)	1105-1118	
	5/9	佐藤	UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia	Leukemia	2023	doi: 10.1038	s41375-023-01906-z.	
			Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial	Lancet	2023	401(10388)	1571-1583	
		古本	Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial	Blood	2023	141(14)	1666-1674	
	5/16	桐野	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features	Leukemia	2020	34(5)	1373-1382	
			Long Term Follow up of Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis Treated with Bendamustine and Dexamethasone in a Phase 2 Trial	Blood	2017	130(1)	1838	
			Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia)	Adv Hematol	2022	doi: 10.1155/2022/1182384		
		渡辺	Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study	Blood adv	2023	doi:10.1182		
	5/23	宮崎	MDS、AMLの診断と治療の変遷についての解説					
		クリニック学生	Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial	Lancet	2023	401(10388)	1571-1583	
	5/30	田口(留学報告)						
	6/6	一瀬	Primary Effusion Lymphoma: A Timely Review on the Association with HIV, HHV8, and EBV	Diagnostics(Basel)	2022	12(3)	713	
			Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis	Blood adv	2020	4(18)	4442-4450	
		坂本	Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse	Cancer Discov	2022	14(6)	1449-1461	
	6/13	加藤						
		清水						
	6/20	松本						
		安東						
	6/27	山田	Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase 3 Trial	JCO	2023 Jan	41(2)	327-335	
			Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial	JAMA Oncol	2020 Jun	6(6)	872-880	
			Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma	N Engl J Med	2010 Aug	363(7)	640-52	
		クリニック学生						
	7/4	糸永	Nat Med.2023;29:422 N Engl J Med. DOI:10.1056 N Engl J Med.2022;388:1284 Nature .2022 ;603:934 Nat Med.2023;29:803 Transplant Cell Ther.2023 J Clin Oncol.2022 ;41:343					
		児嶋	Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis	NEJM	2023	388	2338-2348	

	7/11	渡辺	Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study	Lancet		2008	371(9624)	1579-86	
			Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic cell transplantation	Ann Hematol		2023	102(6)	1537-1547	
			Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease	Front Immunol		2022	13	959638	
			Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence	Bone Marrow Tra		2021	56(10)	2355-2366	
		蓬萊	Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes	J Clin Oncol		2023	41(15)	2827-2842	
	7/18	クリクラ学生	Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma	N Engl J Med		2023	389(2)	148-157	
		桐野	Lancet.2023 Jul 29;402(10399):373-385 J Clin Oncol.2023 Oct 1;41(28):4486-4496						
	7/25	児嶋	J Clin Oncol.2023;41(10):1820-42 N Engl J Med.2021;385(3):228-238 Blood.2021;1388(22):2278-89						
		佐藤	Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia	Leukemia		2023	37(4)	765-775	
	9/26	坂本	Transplant Cell Ther.2023 Oct;29(10):622-631 J Clin Invest.2023 Aug 1;133(15)						
		一瀬	Pharmacological GLUT3 salvage augments the efficacy of vitamin C-induced TET2 restoration in acute myeloid leukemia	Leukemia		2023	37(8)	1638-48	
	10/3	山田	Hematopoietic Cell Transplantation for Primary Plasma Cell Leukemia: Results from the Center for International Blood and Marrow Transplant Research	Leukemia		2012	26(5)	1091-1097	(敬称略)
			Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features	blood		2022	139(17)	2666-2672	
		宮崎	Multiparameter prediction of myeloid neoplastic risk	Nature Genetics		2023	55(9)	1523-1530	
	10/10	渡辺	Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation	Blood Cancer J	2023 Jun		13(1)	95	
			Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas	Acta Derm Venereol	2022 Mar		102	adv00676.	
			Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma	Clin Lymphoma M	2018 Jan		18(1)	e85-e93	
		田口	Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement	Cell	2023 Oct 12		186(21)	4528-4545	
	11/7	桐野	Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in the B-ALL-10 Study	blood	2022 dec		140(sup2)		
			Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	Lancet Haematol	2023 jan		10(1)	e24-e34	
			The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study	blood	2022 Nov		140(sup1)	8966-8968	
		加藤	Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial	cancer cell	2023 Oct		41(10)	1705-1716	
	11/14	安東	Systematic investigation of mitochondrial transfer between cancer cells and T cells at single-cell resolution	cancer cell	2023 Oct		41(10)	1788-1802	
		山田	Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease	cancer cell	2023 Jun		41(6)	1032-1047	
	11/21	児嶋	Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCl Consortium ALL trials	blood adv	2023 Sep		7(18)	5234-5245	
			Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial	blood adv	2023 Oct		7(19)	5996-6004	
		糸永	Epitope editing enables targeted immunotherapy of acute myeloid leukaemia	nature	2023 Sep		621(7978)	404-414	
	11/28	蓬萊	Genetic basis and molecular profiling in myeloproliferative neoplasms	blood	2023 Apr		141(16)	1909-1921	
			GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis	leukemia	2018 Jul		32(7)	1631-1642	
			MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis	JCO	2018 Jun		36(17)	1769-1770	
			Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management	Am J Hematol	2018 Dec		93(12)	1551-1560	
			MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Myelofibrosis	JCO	2023 Nov		41(32)	4993-5004	
		渡辺	A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: U	blood	2022 Nov		140(sup1)	532-533	
	12/5	佐藤	Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)	leukemia	2023 Nov		doi: 10.1038	s41375-023-02068-8	
			Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia	leukemia	2023 Dec		37(12)	2395-2403	
		松本	What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?	JCO	2023 Oct		41(29)	4693-4703	
	12/12	田口	Genetic Determinants of Clonal Hematopoiesis and Progression to Hematologic Malignancies in 479,117 Individuals	blood	2023		142(sup1)	811	
			Plasma Proteomic Signature Predicts Risk of Myeloid Neoplasm	blood	2023		142(sup1)	940	
			Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications	blood	2023		142(sup1)	997	
			Genotype-Phenotype Mapping Via Single-Cell Multi-Omics Identifies Therapeutic Vulnerabilities in Vexas Syndrome	blood	2023		142(sup1)	813	
			Clinical Manifestations Are Evolving and Progressive in Patients with Vexas Syndrome	blood	2023		142(sup1)	703	
			Intensive Chemotherapy (IC) Followed By Oral Azacitidine (AZA) Maintenance Versus Venetoclax (VEN) Plus AZA for Patients (pts) with Acute Myeloid Leukemia (AML)	blood	2023		142(sup1)	550	
			Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents	blood	2023		142(sup1)	321	
		古本	Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the	JCO	2023 Oct		41(28)	4497-4510	
	12/19	坂本	Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving	JCO	2023 Oct		23	1097	
		加藤	Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM	JCO	2024 Feb		42(5)	550-561	
			Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma	JCO	2024 Feb		42(5)	538-549	
			Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease	N Engl J Med	2024 Jan		390(4)	326-337	
	1/16	山田	Efficacy and safety of ruxolitinib in steroid-refractory graft- versus-host disease: A meta-analysis	Front Immunol	2022 Aug		4	13	
			Vedolizumab for acute gastrointestinal graft-versus-host disease: A systematic review and meta-analysis	Front Immunol	2022 Nov		11	13	

			Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease	Transplant Cell T	2021 Mar	27(3)	272	
			Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease	N Engl J Med	2020 May 382(1	382(19)	1800-1810	
		安東	Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies	Cancer Cell	2023 Dec	41(12)	2136-2153	
	1/23	松本	Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation	Biol Blood Marrow Transplant	2016 Feb	22(2)	240-247	
			Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic stem cell transplantation	BMC Cancer	2023 Aug	23(1)	764	
			Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis	Haematologica	2018 Feb	103(2)	237-245	
			Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndromes	Cancer Sci	2021 Sep	112(9)	3636-3644	
		クリクラ学生	Case 8-2023: A 71-Year-Old Woman with Refractory Hemolytic Anemia	N Engl J Med	2023 Mar	388(11)	1032-1041	
	1/30	桐野	Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML	Blood Adv	2024 Jan	8(2)	343-352.	
			Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1	Blood Adv	2022 Feb	6(3)	882-890	
			Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML	JCO	2024 Jan			
		蓬萊	Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational phase 2 study	Lancet	2024 Jan	403(10423)	249-260	
	2/6	児嶋	Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease	N Engl J Med	2024 Jan	390(4)	326-337	
			Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia	Blood Adv	2023 Aug	7(16)	4291-4301	
			Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia	N Engl J Med	2023 Jan	388(4)	319-332	
		佐藤	Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells	Blood	2024 Jan	143(1)	32-41	
	2/20	坂本	Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia	N Engl J Med	2016 Aug	375(8)	740-53	
			Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label phase 3 trial	Lancet Haematol	2017 Aug	4(8)	e387-e398	
			Management of important adverse events associated with inotuzumab ozogamicin: expert panel review	Bone Marrow Transplant	2018 Apr	53(4)	449-456	
			Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation	Haematologica	2023 Dec			
		クリクラ学生	Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma	N Engl J Med	2024 Jan	390(4)	301-313	
	3/19	桐野	Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax	Blood Adv	2024 Feb	8(4)	927-935	
		渡辺	Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma	Blood Adv	2024 Jun	8(11)	2601-2611	
			Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma	Cancer Sci	2021 Jun	112(6)	2426-2435	
	4/2	児嶋	Correlation analysis between auto-immunological and mutational profiles in myelodysplastic syndromes	Inflamm Res	2023 Aug	72(8)	1695-1707	
		安東	Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers	Cancer Cell	2024 Apr	8:42(4)	568-582	
			Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer	Nature	2017 Jul	547(7662)	222-226	
			Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation	Front Immunol	2021 Mar	9:12	636568	
	4/9	加藤	Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma	Nat Med	2024 Feb	30(2)	507-518	
		糸永	移植学会の報告					
	4/16	クリクラ学生	Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial	Blood	2023 Oct	142(14)	1208-1218	
		蓬萊	DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality	Blood Adv	2020 Jul	14:4(13)	3024-3033	
			CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma	Blood	2021 Dec	138(24)	2499-2513	
			Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality	Blood Adv	2024 Apr	23:8(8)	1857-1868	
			Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations	Blood	2023 Sep	142(10)	865-877	
	4/23	山田	Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia	Blood Adv	2024 Apr	9:8(7)	639-1650	
		坂本	Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis	N Engl J Med	2023 Jun	388(25)	2338-2348	
			Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation	Bone Marrow Transplant	2021 Jan	56(1)	129-136	
			Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor	Bone Marrow Transplant	2024 Mar	59(3)	344-349	
			Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched unrelated donor	Blood Cancer J	2024 Feb	14(1)	31	
	4/30	宮崎	T-cell dysfunctions in myelodysplastic syndromes	Blood	2024 Apr	143(14)	1329-1343	
		佐藤	Prognostic impact of CEBPA mutational subgroups in adult AML	Leukemia	2024 Feb	38(2)	281-290	
			Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis	N Engl J Med	2024 Apr	390(16)	1467-1480	
	5/7	南野	Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial	Blood	2023 Oct	5:142(14)	1208-1218	
		松本	Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia	Am J Hematol	2024 Apr	99(4)	615-624	
			How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia	Leukemia	2019 Dec	33(12)	2795-2804	
			Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A	Am J Hematol	2022 Nov	97(11)	E416-E419	
			Safety and efficacy of 7-day administration of azacitidine and venetoclax combination therapy (7+7 therapy)	Rinsho Ketsueki	2024	65(3)	135-141	
	5/14	田口	Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances	Blood	2023 Mar	141(13)	1513-1523	
			Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome	Nat Commun	2021 Feb	12(1)	1334	

			Somatic genetic rescue of a germline ribosome assembly defect	Nat Commun	2021 Aug	12(1)	5044	
		糸永	Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers	Cancer Cell	2024 May	42(5)	850-868	
	5/21	クリクラ学生	Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image data set	Blood	2021 Nov	138(20)	1917-1927	
		渡辺	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy	Blood	2017 Nov	23;130	2243-2250	
			Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary R	Blood	2020 Nov	136 (Supplement	22-24	
			Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study	Blood	2021 Dec	138(22)	2278-2289	
			Axatilimab for chronic graft-versus-host disease after of at least two prior systemic therapies: results of phase I/II study	J Clin Oncol	2023 Apr	41(10)	1864-1875	
	5/4	研修医	Differential impact of BTK active site inhibitors on the conformational state of full-length BTK	Elife	2020 Nov	9	e60470	
		桐野	A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia	Blood Adv	2024 May	8(10)	2342-2350	
			Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease	N Engl J Med	2024 Jan	390(4)	326-337	
	6/4	坂本	Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukemia	Lancet Haematol	2024 May	11(5)	e324-e335	
		加藤	Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas	Blood	2024 Mar	143(13)	1231-1241	
	6/18	学生	Asciminib in Newly Diagnosed Chronic Myeloid Leukemia	N Engl J Med	2024 May			
		山田	Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL	JCO	2024 Mar	10;42(8)	881-885	
			Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults	N Engl J Med	2020 Oct	22;383(17)	1613-1623	
	7/2	勝岡	Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy	N Engl J Med	2024 Jun	13;390(22)	2074-2082	
			A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia	N Engl J Med	2024 Jun	390(23)	2178-2190	
		安東	Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers	Cancer Cell	2024 May	42(5)	850-868	
	7/9	南野	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société	Am J Hematol	2021 Jul	96(7)	834-845	
			Progress of Hematopoietic Stem Cell Transplantation and Radiotherapy in the Treatment of Extranodal NK/T Cell Lymphoma	Front Oncol	2022 Feb 16	12	832428	
			Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Tran	Biol Blood Marro	2018 Dec	24(12)	471-2478	
		佐藤	Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes	Blood Adv	2024 May	8(10)	2442-2454	
	7/16	安東	An age-progressive platelet differentiation path from hematopoietic stem cells causes exacerbated thrombosis	Cell	2024 Jun	6;187(12)	3090-3107	
			Clonal hematopoiesis driven by mutated DNMT3A promotes inflammatory bone loss	Cell	2024 Jul	187(14)	3690-3711	
		クリクラ学生	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed S	JCO	2018 Sep	36(26)	2684-2692	
	7/23	糸永	Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of	Transplant Cell T	2024 Jul	6:S2666-6367(24	00487-1	
			A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy	Nat Med	2024 Jul	doi: 10.1038/s41591-024-03084-6		
		田口	Reconstructing Complex Cancer Evolutionary Histories from Multiple Bulk DNA Samples Using Pairtree	Blood Cancer Dis	2022 May	3(3)	208-219	
			CALDER: Inferring Phylogenetic Trees from Longitudinal Tumor Samples	Cell Syst	2019 Jun	8(6)	514-522	
			The implications of clonal genome evolution for cancer medicine	N Engl J Med	2013 Feb	368(9)	842-51	
			Clonal evolution in leukemia	Nat Med	2017 Oct	23(10)	1135-1145	
			Cancer evolution: Darwin and beyond	EMBO J	2021 Sep	40(18)	e108389	
			SnapShot: Tumor evolution	Cell	2021 Mar	184(6)	1650-1650.e1	
	7/30	坂本	Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT	Blood	2024 Jul	144(3)	323-333	
			Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL	J Clin Oncol	2024 Jul	JCO2400272		
			High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma	Lancet Haematol	2024 Mar	11(3)	e196-e205	
		桐野	Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation	Blood neoplasia	2024 Sep	1 (3)	1 (3): 100022.	